An interventional study of Drug-eluting stenting plus aspirin and clopidogrel or ticagrelor and Aspirin and clopidogrel or ticagrelor in Ischemic Stroke and Vertebral Artery Stenosis, sponsored by Xuanwu Hospital, Beijing. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Xuanwu Hospital, Beijing · Not applicable, Interventional, and Treatment
Among 52 studies in Ischemic Stroke by Xuanwu Hospital, Beijing — 30 open to participants now, 31 under way, 2 of them phase 3. Ischemic Stroke · Xuanwu Hospital, Beijing.
Among the 52 studies in Ischemic Stroke by Xuanwu Hospital, Beijing, this one is the 11th largest by planned enrollment of the 28 interventional ones that give a count, is one of 9 that started in 2023, is one of 14 with no phase, reaches primary completion later than 20 of the 30 other live ones, and was the 21st registered.
2,612 studies on the registry are indexed under Ischemic Stroke; 971 are open to participants now.
Browse Ischemic Stroke studies →30 of the 52 studies in Ischemic Stroke by Xuanwu Hospital, Beijing are open now, in 1 country. Recruiting first, the newest first:
Xuanwu Hospital, Beijing · Sites in China
Xuanwu Hospital, Beijing · Sites in China
Xuanwu Hospital, Beijing · Sites in China
Xuanwu Hospital, Beijing · Sites in China
Xuanwu Hospital, Beijing · Sites in China
By country, each count listing its studies:
Of the 655 Ischemic Stroke studies recruiting now, 394 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 3 · Phase 4 6
First in 2012; this study’s year is marked. 9 started in 2023.
This study's planned enrollment of 472 is above the median of 120 across 1,776 interventional studies indexed under Ischemic Stroke.
Median enrollment 325 across the 28 interventional studies, 350 across the 24 observational. Of the 14 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Xuanwu Hospital, Beijing is the lead sponsor of 363 studies on the registry; 230 are open to participants now.
13 of the studies in Ischemic Stroke by Xuanwu Hospital, Beijing that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06658197Phase 3Xuanwu Hospital, BeijingEfficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke | 2026-12-01 |
| NCT07419997Xuanwu Hospital, BeijingA Multicenter, Retrospective, Observational Cohort Study on Intravenous Thrombolysis Beyond the Time Window for Acute Ischemic Stroke | 2026-12-29 |
| NCT07519044Xuanwu Hospital, BeijingSafety and Efficacy of Adjunctive GM1 to Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion | 2027-01-31 |
| NCT05232240Xuanwu Hospital, BeijingBlood Pressure Variability in Non-hypertensive Patients With Ischemic Cerebrovascular Disease | 2027-02 |
| NCT07882030Xuanwu Hospital, BeijingEarly Administration of Angong Niuhuang Pill for Disabling Acute Ischemic Stroke (EAGER Trial) | 2027-07 |
Among the 52 studies in Ischemic Stroke by Xuanwu Hospital, Beijing, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Posterior circulation stroke accounts for 20% of all ischemic stroke. Approximately one quarter of posterior circulation strokes are due to stenosis in the vertebral artery and basilar artery.
Two previous randomized controlled trials focusing on vertebral artery stenting, the Vertebral Artery Stenting Trial (VAST) and the Vertebral Artery Ischaemia Stenting Trial (VIST) were underpowered because they failed to reach target recruitment, and both the trials found no difference in risk of the primary outcome between the stenting group and medical group.
The drug-eluting stenting versus medical therapy alone for patients with extracranial vertebral artery stenosis (VISTA) trial, is a government-funded, prospective, multicenter, randomized controlled trial. It will recruit patients with 3 months stroke or TIA caused by 70-99% stenosis of extracranial vertebral artery (V1-2 segments). Only high-volume center with a proven track record will enroll patients. Patients will be randomized (1:1) to best medical treatment alone or medical treatment plus stenting. Primary outcome is a composite of any fatal or non-fatal stroke within 30 days after randomization, or ischemic stroke in the territory of the target artery beyond 30 days to 1 year. The VISTA trial will be conducted in 30 sites in China and aims to have a sample size of 472 subjects (stenting, 236; medical treatment, 236). Recruitment is expected to be finished by Sep, 2025. Patients will be followed for 1 year at first stage. Long-term follow-ups till 3 years or longer is also preplanned. The first stage of the trial is scheduled to complete in 2027.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All the participants in this group will be performed with extracranial vertebral artery sirolimus-eluting stenting plus best medical treatment including Aspirin 100mg per day + Clopidogrel 75mg per day or Ticagrelor 90mg twice per day for 6 months and mono anti-platelet therapy thereafter.
Procedure: Drug-eluting stenting plus aspirin and clopidogrel or ticagrelor
All the participants in this group will be given medical therapy including Aspirin 100mg per day + Clopidogrel 75mg per day or Ticagrelor 90mg twice per day for 6 months and mono anti-platelet therapy thereafter.
Drug: Aspirin and clopidogrel or ticagrelor · Procedure: mono anti-platelet therapy
All the participants in this group will be performed with extracranial vertebral artery sirolimus-eluting stenting plus medical therapy including aspirin 100mg per day + clopidogrel 75mg per day or ticagrelor 90mg twice per day for 6 months and mono anti-platelet therapy thereafter.
Also known as: Sirolimus-eluting stenting plus dual antiplatelet therapy
All the participants in this group will be given medical therapy including aspirin 100mg per day + clopidogrel 75mg per day or ticagrelor 90mg twice per day for 6 months and mono anti-platelet therapy thereafter.
mono anti-platelet therapy
Any fatal or non-fatal stroke within 30 days after randomization, or ischemic stroke in the territory of the target artery beyond 30 days to 1 year.
The number of participants who suffer from any fatal or non-fatal stroke within 30 days after randomization, or ischemic stroke in the territory of the target artery beyond 30 days to 1 year.
Time frame: 1 year
Fatal or non-fatal stroke within 30 days
The number of participants who suffer from fatal or non-fatal stroke within 30 days after randomization.
Time frame: within 30 days
Ischemic stroke in the territory of the target artery beyond 30 days to 1 year
The number of participants who suffer from ischemic stroke in the territory of the target artery beyond 30 days to 1 year.
Time frame: beyond 30 days to 1 year
Ischemic stroke in the territory of the target artery within 1 year
The number of participants who suffer from ischemic stroke in the territory of the target artery within 1 year.
Time frame: within 1 year
Crescendo TIA in the territory of the target artery within 1 year
The number of participants who suffer from crescendo TIA in the territory of the target artery within 1 year.
Time frame: within 1 year
Fatal stroke within 1 year
The number of participants who suffer from fatal stroke within 1 year.
Time frame: within 1 year
Disabling stroke (defined by a modified Rankin Scale Score of ≥3) within 1 year
The number of participants who suffer from disabling stroke (defined by a modified Rankin Scale Score of ≥3) within 1 year.
Time frame: within 1 year
Any stroke within 1 year
The number of participants who suffer from any stroke within 1 year.
Time frame: within 1 year
Any stroke, myocardial infarction or death within 1 year
The number of participants who suffer from any stroke, myocardial infarction or death within 1 year.
Time frame: within 1 year
All cause mortality within 1 year
The number of participants who die of any cause within 1 year.
Time frame: within 1 year
Symptomatic cerebral hemorrhage within 1 year
The number of participants who suffer from symptomatic cerebral hemorrhage within 1 year.
Time frame: within 1 year
Modified Rankin Scale (mRS) score (0-5, higher score refers to a worse outcome)
Modified Rankin Scale (mRS) score at 1 year.
Time frame: at 1 year
In-stent restenosis (Stenosis ≥ 50%)
In-stent restenosis (Stenosis ≥ 50%) at 1 year. Performing CTA or DSA to evaluate the stenosis degree.
Time frame: at 1 year
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2023 (actual). Primary completion is estimated for Nov 2027, 51 months after the start.
Of 572 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 51 months is above that.
Counting every sponsor, half of 653 studies reached it within 27 months; a quarter within 14 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.